IXICO reports 26% revenue increase in first half of 2025

Published 16/04/2025, 07:22
IXICO reports 26% revenue increase in first half of 2025

LONDON - IXICO plc (AIM: IXI), the AI-powered medical imaging analytics company specializing in neuroscience, announced today that its revenues for the first six months ending March 31, 2025, have increased by 26% compared to the same period last year. The company is expected to report revenues of £3.2 million, up from £2.5 million in the prior year, aligning with or potentially exceeding its financial guidance.

The company’s order book stood at £13.1 million as of March 31, 2025, showing a slight increase from £12.7 million in the first half of the previous year. This includes new projects related to Alzheimer’s Disease research. Additionally, IXICO reported a robust cash balance of £5.0 million, a significant rise from £2.5 million, and remains debt-free following a capital raise earlier in the year.

IXICO also noted a reduced loss before interest, tax, depreciation, and amortisation, which is expected to be £0.7 million compared to a £1.3 million loss in the first half of 2024.

The company has been actively investing in expanding its operational services across the US time zone and appointing key roles, both commercial and operational, to enhance its visibility and attractiveness in this crucial market. Furthermore, IXICO is differentiating its imaging biomarker analysis pipelines for Alzheimer’s and Parkinson’s diseases, aiming to secure more contracts in these areas in the second half of 2025 and into 2026.

The company’s CEO, Bram Goorden, expressed satisfaction with the new global capabilities, talent, and innovation IXICO has added, leading to new client wins and building on the strong financial performance at the end of 2024. Goorden emphasized the company’s growing position in neurodegenerative disease research and the potential for accelerated market impact due to IXICO’s differentiated technology platform.

IXICO’s interim results for the first half of 2025 will be released on May 20, 2025. This announcement includes inside information now considered to be in the public domain. The information is based on a press release statement from IXICO plc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.